ICU Medical Inc. (NASDAQ:ICUI) shares gapped up before the market opened on Tuesday . The stock had previously closed at $113.27, but opened at $113.33. ICU Medical shares last traded at $114.58, with a volume of 23,246 shares changing hands.

A number of brokerages have recently issued reports on ICUI. Zacks Investment Research downgraded ICU Medical from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Piper Jaffray Cos. reiterated a “neutral” rating and set a $110.00 price objective on shares of ICU Medical in a research report on Saturday, April 23rd.

The stock has a market capitalization of $1.85 billion and a P/E ratio of 37.30. The company’s 50 day moving average price is $110.07 and its 200-day moving average price is $101.27.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Tuesday, May 10th. The company reported $1.14 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.01 by $0.13. The firm had revenue of $89.90 million for the quarter, compared to the consensus estimate of $88.04 million. During the same period in the prior year, the company earned $0.60 EPS. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. On average, equities analysts forecast that ICU Medical Inc. will post $4.43 EPS for the current year.

In related news, VP Steven Riggs sold 20,000 shares of the company’s stock in a transaction dated Wednesday, June 29th. The shares were sold at an average price of $110.00, for a total transaction of $2,200,000.00. Following the completion of the sale, the vice president now owns 21,378 shares of the company’s stock, valued at $2,351,580. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Joseph R. Saucedo sold 1,875 shares of the company’s stock in a transaction dated Tuesday, May 10th. The stock was sold at an average price of $105.00, for a total transaction of $196,875.00. Following the sale, the director now directly owns 3,431 shares of the company’s stock, valued at approximately $360,255. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have modified their holdings of ICUI. Airain ltd acquired a new position in shares of ICU Medical during the fourth quarter valued at approximately $1,009,000. Sei Investments Co. increased its position in shares of ICU Medical by 38.1% in the fourth quarter. Sei Investments Co. now owns 9,629 shares of the company’s stock valued at $1,086,000 after buying an additional 2,657 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of ICU Medical by 9.0% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 10,296 shares of the company’s stock valued at $1,161,000 after buying an additional 846 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its position in shares of ICU Medical by 73.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 13,586 shares of the company’s stock valued at $1,533,000 after buying an additional 5,742 shares during the last quarter. Finally, Comerica Bank increased its position in shares of ICU Medical by 2.4% in the fourth quarter. Comerica Bank now owns 14,938 shares of the company’s stock valued at $1,550,000 after buying an additional 348 shares during the last quarter.

ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.